A "uniquely Australian" mix of variants will make treating severe COVID-19 more challenging, according to new research, with fewer drugs left in the "cupboard" that are effective against new strains of the virus.
A new paper spearheaded by the Kirby Institute in Sydney looked at 15 COVID-19 variants in circulation in Australia in 2022, and how successful two types of monoclonal antibodies — Evusheld and Sotrovimab — were in offering protection.